Evidence map›Paper›PMID 31833801›Full record

Trial reportDiabetes technology & therapeutics2020

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.

James Thrasher, Sarit Polsky, Lionel Hovsepian, Irene Nowotny, Suzanne Pierre, Béatrice Bois De Fer, Anuj Bhargava, Bhaswati Mukherjee, Satish K Garg

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes technology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03436498 (Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03436498 phase1completednot on this map

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)

TypeinterventionalSponsorSanofiRan2018 to 2018Enrolled45ConditionsType 1 Diabetes MellitusArmsInsulin aspart SAR341402, Insulin aspart
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James ThrasherMedical Investigations, Inc., Little Rock, Arkansas.
Sarit PolskyDepartment of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Denver, Colorado.
Lionel HovsepianSanofi, Paris, France.
Irene NowotnySanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
Suzanne PierreSanofi, Paris, France.
Béatrice Bois De FerSanofi, Paris, France.
Anuj BhargavaIowa Diabetes & Endocrinology Research Center, West Des Moines, Iowa.
Bhaswati MukherjeeSanofi, Paris, France.
Satish K GargDepartment of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Denver, Colorado.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 1AdultAgedBiosimilar PharmaceuticalsBlood GlucoseCross-Over StudiesFemaleHumansHypoglycemic AgentsInsulin AspartInsulin Infusion SystemsMaleMiddle AgedBiosimilar PharmaceuticalsBlood GlucoseHypoglycemic AgentsInsulin AspartBiosimilarContinuous subcutaneous insulin infusionFollow-on productInfusion set occlusionInsulin aspartSAR341402

Identifiers

PMID31833801
PMCPMC7478191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.